Literature DB >> 34811876

Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage.

Kaoru Takasaki1, David Hehir2,3, Leslie Raffini4,5, Benjamin J Samelson-Jones4,5,6, Evelyn Shih1,7,8, Aleksandra Sarah Dain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34811876      PMCID： PMC9038625          DOI： 10.1002/pbc.29484

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  9 in total

1.  Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).

Authors:  Philip Connor; Mayte Sánchez van Kammen; Anthonie W A Lensing; Elizabeth Chalmers; Krisztián Kállay; Kerry Hege; Paolo Simioni; Tina Biss; Fanny Bajolle; Damien Bonnet; Sebastian Grunt; Riten Kumar; Olga Lvova; Rukhmi Bhat; An Van Damme; Joseph Palumbo; Amparo Santamaria; Paola Saracco; Jeanette Payne; Susan Baird; Kamar Godder; Veerle Labarque; Christoph Male; Ida Martinelli; Michelle Morales Soto; Jayashree Motwani; Sanjay Shah; Helene L Hooimeijer; Martin H Prins; Dagmar Kubitza; William T Smith; Scott D Berkowitz; Akos F Pap; Madhurima Majumder; Paul Monagle; Jonathan M Coutinho
Journal:  Blood Adv       Date:  2020-12-22

2.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Mark Crowther; John W Eikelboom; C Michael Gibson; John T Curnutte; John H Lawrence; Patrick Yue; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Andrew M Demchuk; Daniel J Pallin; Mauricio Concha; Shelly Goodman; Janet Leeds; Sonia Souza; Deborah M Siegal; Elena Zotova; Brandi Meeks; Sadia Ahmad; Juliet Nakamya; Truman J Milling
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

3.  Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

Authors:  Christoph Male; Anthonie W A Lensing; Joseph S Palumbo; Riten Kumar; Ildar Nurmeev; Kerry Hege; Damien Bonnet; Philip Connor; Hélène L Hooimeijer; Marcela Torres; Anthony K C Chan; Gili Kenet; Susanne Holzhauer; Amparo Santamaría; Pascal Amedro; Elizabeth Chalmers; Paolo Simioni; Rukhmi V Bhat; Donald L Yee; Olga Lvova; Jan Beyer-Westendorf; Tina T Biss; Ida Martinelli; Paola Saracco; Marjolein Peters; Krisztián Kállay; Cynthia A Gauger; M Patricia Massicotte; Guy Young; Akos F Pap; Madhurima Majumder; William T Smith; Jürgen F Heubach; Scott D Berkowitz; Kirstin Thelen; Dagmar Kubitza; Mark Crowther; Martin H Prins; Paul Monagle
Journal:  Lancet Haematol       Date:  2019-11-05       Impact factor: 18.959

4.  Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.

Authors:  Jacqueline Halton; Leonardo R Brandão; Matteo Luciani; Lisa Bomgaars; Elizabeth Chalmers; Lesley G Mitchell; Ildar Nurmeev; Anjali Sharathkumar; Pavel Svirin; Kirill Gorbatikov; Igor Tartakovsky; Monika Simetzberger; Fenglei Huang; Zhichao Sun; Jörg Kreuzer; Savion Gropper; Paul Reilly; Martina Brueckmann; Manuela Albisetti
Journal:  Lancet Haematol       Date:  2020-12-05       Impact factor: 18.959

5.  PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)-Rationale and Design.

Authors:  Sarah H O'Brien; Danshi Li; Lesley G Mitchell; Thomas Hess; Pamela Zee; Donald L Yee; Jane W Newburger; Lillian Sung; Vilmarie Rodriguez
Journal:  Thromb Haemost       Date:  2019-03-12       Impact factor: 5.249

6.  Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE).

Authors:  Katharina Thom; Anthonie W A Lensing; Ildar Nurmeev; Fanny Bajolle; Damien Bonnet; Gili Kenet; M Patricia Massicotte; Zeynep Karakas; Joseph S Palumbo; Paola Saracco; Pascal Amedro; Juan Chain; Anthony K Chan; Takanari Ikeyama; Joyce C M Lam; Cynthia Gauger; Ákos Ferenc Pap; Madhurima Majumder; Dagmar Kubitza; William T Smith; Scott D Berkowitz; Martin H Prins; Paul Monagle; Guy Young; Christoph Male
Journal:  Blood Adv       Date:  2020-10-13

7.  A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study.

Authors:  R Mark Payne; Kristin M Burns; Andrew C Glatz; Danshi Li; Xiaodong Li; Paul Monagle; Jane W Newburger; Elizabeth A Swan; Olivia Wheaton; Christoph Male
Journal:  Am Heart J       Date:  2019-08-09       Impact factor: 4.749

8.  Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

Authors:  Deborah M Siegal; John T Curnutte; Stuart J Connolly; Genmin Lu; Pamela B Conley; Brian L Wiens; Vandana S Mathur; Janice Castillo; Michele D Bronson; Janet M Leeds; Florie A Mar; Alex Gold; Mark A Crowther
Journal:  N Engl J Med       Date:  2015-11-11       Impact factor: 91.245

9.  Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.

Authors:  Manuela Albisetti; Arno Schlosser; Martina Brueckmann; Savion Gropper; Stephan Glund; Igor Tartakovsky; Leonardo R Brandão; Paul A Reilly
Journal:  Res Pract Thromb Haemost       Date:  2017-11-17
  9 in total
  1 in total

Review 1.  Practical Considerations for Use of Direct Oral Anticoagulants in Children.

Authors:  Hilary Whitworth; Leslie Raffini
Journal:  Front Pediatr       Date:  2022-04-01       Impact factor: 3.569
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.